Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
OBJECTIVE
This study aimed to evaluate the length of stay (LOS), costs, and treatment consistency among patients hospitalized with community-acquired pneumonia (CAP) initially treated with intravenous (IV) moxifloxacin 400 mg or IV levofloxacin 750 mg.


METHODS
Adults with CAP receiving IV moxifloxacin or IV levofloxacin for > or =3 days were identified in the Premier Perspective comparative database. Primary outcomes were LOS and costs. Secondary outcomes included treatment consistency, which was defined as 1) no additional IV moxifloxacin or levofloxacin after > or =1 day off study drug; 2) no switch to another IV antibiotic; and 3) no addition of another IV antibiotic.


RESULTS
A total of 7720 patients met inclusion criteria (6040 receiving moxifloxacin; 1680 receiving levofloxacin). Propensity matching created two cohorts (1300 patients each) well matched for demographic, clinical, hospital, and payor characteristics. Before the patients were matched, mean LOS (5.87 vs. 5.46 days; P = 0.0004) and total costs per patient ($7302 vs. $6362; P < 0.0001) were significantly greater with moxifloxacin. After the patients were matched, mean LOS (5.63 vs. 5.51 days; P = 0.462) and total costs ($6624 vs. $6473; P = 0.476) were comparable in both cohorts. Treatment consistency was higher for moxifloxacin before (81.0% vs. 78.9%; P = 0.048) and after matching (82.8% vs. 78.0%; P = 0.002).


CONCLUSIONS
In-hospital treatment of CAP with IV moxifloxacin 400 mg or IV levofloxacin 750 mg was associated with similar hospital LOS and costs in propensity-matched cohorts.
Friedman
Howard
H
Analytic Solutions LLC, 26 Prince Street, New York, NY 10012, USA. howard@analytic-consulting.com
Song
Xue
X
Crespi
Simone
S
Navaratnam
Prakash
P
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000191:economics; D016001:Confidence Intervals; D016208:Databases, Factual; D003953:Diagnosis-Related Groups; D005260:Female; D024841:Fluoroquinolones; D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007275:Injections, Intravenous; D007902:Length of Stay / Q000191:economics* / Q000706:statistics & numerical data; D064704:Levofloxacin; D016015:Logistic Models; D008297:Male; D000077266:Moxifloxacin; D015999:Multivariate Analysis; D015242:Ofloxacin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000191:economics*; D057216:Propensity Score; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000191:economics; D011804:Quinolines / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D012189:Retrospective Studies; D013223:Statistics as Topic; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin